Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.09. | Fusion von NLS Pharmaceutics und Kadimastem: SEC erteilt Freigabe | 1 | Investing.com Deutsch | ||
10.09. | SEC clears registration for NLS Pharmaceutics and Kadimastem merger | 1 | Investing.com | ||
NLS PHARMACEUTICS Aktie jetzt für 0€ handeln | |||||
10.09. | Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger | 56 | PR Newswire | ZURICH and NESS ZIONA, Israel, Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous... ► Artikel lesen | |
04.09. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
25.08. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
06.08. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
17.07. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
30.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
16.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.06. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders | 965 | PR Newswire | ZURICH, June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
06.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
21.05. | NLS Pharmaceutics präsentiert Mazindol-Studie auf ASCP-Tagung | 2 | Investing.com Deutsch | ||
21.05. | NLS Pharmaceutics to present Mazindol study at ASCP Meeting | 2 | Investing.com | ||
16.05. | NLS Pharmaceutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
05.05. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
24.04. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.04. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.04. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models | 387 | PR Newswire | Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics
Favorable results support potential expansion into high-value... ► Artikel lesen | |
31.03. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
31.03. | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement | 595 | ACCESS Newswire | The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 38,460 | +0,40 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 18,090 | 0,00 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
MINERALYS THERAPEUTICS | 37,290 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
CG ONCOLOGY | 37,510 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
SCISPARC | 4,365 | 0,00 % | Morning Market Movers: SciSparc, HIND, SQFT, FGNX See Big Swings | BEIJING (dpa-AFX) - At 7:55 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
MODERNA | 21,150 | +0,74 % | BioNTech und Moderna: Impf-Alarm lässt Aktien abschmieren | Die Aktien von BioNTech stehen am Freitag massiv unter Druck. Das Papier verliert rund zehn Prozent, nachdem die Washington Post über neue Pläne der Trump-Regierung berichtet hat. Demnach wollen Gesundheitsbeamte... ► Artikel lesen | |
EVOTEC | 6,214 | +1,04 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
LENZ THERAPEUTICS | 42,230 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 44,030 | +4,83 % | Praxis Precision Medicines: Piper Sandler bestätigt "Overweight" nach positiven Studiendaten | ||
JANUX THERAPEUTICS | 23,460 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
BEAM THERAPEUTICS | 22,470 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
PHATHOM PHARMACEUTICALS | 11,000 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 35,430 | -0,95 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 40,060 | 0,00 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential | ||
RECURSION PHARMACEUTICALS | 4,720 | 0,00 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock |